Stockreport

Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data [Seeking Alpha]

Zymeworks Inc.  (ZYME) 
Last zymeworks inc. earnings: 3/2 04:15 pm Check Earnings Report
US:NYSE Investor Relations: ir.zymeworks.com/overview
PDF The company's flagship drug, Zanidatamab, is in phase 3 clinical trials and has significant market potential for biliary tract cancer. Zymeworks utilizes proprietary [Read more]